Clinical trials: SARS-COV2 Virus
COVID-19
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
- Trial name
- CCBCRISIS04 (NCT05166876)
- Testing
- Brequinar Sodium, Dipyridamole 75 MG
- Where
- 7 sites in India
- Volunteers
- 26 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19, Upper Respiratory Tract Infections
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.
- Trial name
- NCT05252468
- Testing
- TaffiX™
- Where
- Bulgaria
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
SARS-CoV-2
Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021
This is an open-label study enrolling healthy adults that participated in Study ARCT-021-01 (the Parent Study). Participants will receive either a single injection of ARCT-021 or no injection and be followed for up to 365 days.
- Trial name
- NCT04728347
- Testing
- ARCT-021
- Where
- Singapore
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
SARS-CoV-2
A Study of S-268019 for the Prevention of COVID-19
The main purpose of this study is to assess the efficacy of S-268019-b for the prevention of COVID-19 in the initial vaccination period prior to crossover in participants without evidence of infection before vaccination as…
- Trial name
- NCT05212948
- Testing
- S-268019-b
- Where
- Vietnam
- Volunteers
- 9,902 people, healthy volunteers welcome
- Sponsor
- Shionogi
SARS-CoV-2 Infection
Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.
An open label, randomized, dose comparison, sequential cohorts study design in healthy volunteers (young adults) is a frequently used design in vaccine Phase 1 studies.
- Trial name
- NCT05385991
- Testing
- ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
- Where
- 6 sites in Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- ACM Biolabs
COVID-19
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19.
- Trial name
- NCT04362189
- Testing
- HB-adMSC
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hope Biosciences Research Foundation
SARS-COV2 Infection
Validation of HyperDetector for SARS-CoV-2
To evaluate the HyperDetector as a method to rapidly screen SARS-CoV-2 To determine the sensitivity and specificity of the screening assay performed on oral swab and saliva specimens, compared to a validated RT-PCR COVID-19…
- Trial name
- NCT05124496
- Testing
- Screening Device
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- HyperSpectral APD
COVID-19
Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult…
- Trial name
- NCT04982068
- Testing
- 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
COVID-19
Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants
One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for successive waves, is to better understand and diagnose the infection.
- Trial name
- COVARIANT (NCT05858502)
- Testing
- Blood sample collection, Saliva sample collection, Nasopharyngeal and nasal sample collection
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
COVID-19, SARS-CoV-2 Infection
Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers
Double blind, Multi-Centre study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of…
- Trial name
- BBV152 (NCT04471519)
- Testing
- BBV152A - Phase I, BBV152B - Phase I, BBV152C - Phase I
- Where
- 12 sites in India
- Volunteers
- 755 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19, COVID-19 Pandemic
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
A galectin antagonist prevents viral entry of Sars-CoV-2 virus by blocking the specific terminal on the surface receptors that enables the virus to enter human cells.
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS-CoV2 Infection
- Trial name
- PROTECT (NCT05096052)
- Testing
- Galactomannan
- Volunteers
- 408 people
- Sponsor
- Bioxytran Inc.
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants.
- Trial name
- NCT05736835
- Testing
- CVXGA
- Where
- 10 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
COVID-19 Infection
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting.
- Trial name
- CRISIS2 (NCT04575038)
- Testing
- Brequinar
- Where
- 14 sites in United States
- Volunteers
- 115 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
- Trial name
- NCT04690387
- Testing
- AV-COVID-19, GM-CSF
- Where
- Indonesia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Influenza, Human+COVID-19
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection.
- Trial name
- NCT07464314
- Testing
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
- Where
- 12 sites in United States
- Volunteers
- 225 people
- Sponsor
- GlaxoSmithKline
SARS-CoV-2
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT06354998
- Testing
- Investigational mRNA-1273.815, Licensed Spikevax Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS CoV-2
A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests
The current standard of care for diagnosis of Severe Acute Respiratory Syndrome associated Coronavirus -2 (SARS-CoV-2 ) infection involves sample collection to be prepared and measured via real time-polymerase chain reaction…
- Trial name
- NCT04568356
- Testing
- Direct Antigen Tests for COVID-19
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- E25Bio, Inc.
Covid 19
GlowTest COVID-19 Antigen Home Test Kit QRI Use Study
The objective of the study is to determine the usability of the GlowTest COVID-19 Antigen Home Test in a simulated home use environment.
- Trial name
- NCT05140005
- Testing
- GlowTest COVID-19 Antigen Home Test
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Arion Bio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.